drugset
drugset / Trial / NCT07204080

(TNX-1500) in Kidney Transplant Recipients

NCT07204080 ↗

Phase 2 Not yet recruiting 5 enrolled Ayman Al Jurdi, MD Tonix Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The primary objective is to investigate the safety and efficacy of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.

Timeline

Start
2026-07-01
Primary completion
2028-09-01
Completion
2029-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject TNX-1500 Monoclonal antibody — —

Indications

chronic transplant rejection disease related to solid organ transplantation immunodeficiency disease